Boiron SA (BOI) - Total Assets
Based on the latest financial reports, Boiron SA (BOI) holds total assets worth €602.81 Million EUR (≈ $704.75 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Boiron SA - Total Assets Trend (2001–2025)
This chart illustrates how Boiron SA's total assets have evolved over time, based on quarterly financial data. Also see Boiron SA (BOI) market capitalisation for the company's overall valuation and market capitalisation.
Boiron SA - Asset Composition Analysis
Current Asset Composition (December 2025)
Boiron SA's total assets of €602.81 Million consist of 48.7% current assets and 51.3% non-current assets. Review how much debt does Boiron SA carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 13.2% |
| Accounts Receivable | €104.92 Million | 17.4% |
| Inventory | €98.60 Million | 16.4% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €30.28 Million | 5.0% |
| Goodwill | €89.60 Million | 14.9% |
Asset Composition Trend (2001–2025)
This chart illustrates how Boiron SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See Boiron SA (BOI) share price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Boiron SA's current assets represent 48.7% of total assets in 2025, a decrease from 57.7% in 2001.
- Cash Position: Cash and equivalents constituted 13.2% of total assets in 2025, up from 9.5% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 19.0% of total assets, an increase from 7.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 17.4% of total assets.
Boiron SA Competitors by Total Assets
Key competitors of Boiron SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Piramal Pharma Limited
NSE:PPLPHARMA
|
India | Rs179.65 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Zhejiang Medicine Co Ltd
SHG:600216
|
China | CN¥14.18 Billion |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091
|
China | CN¥1.54 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
Boiron SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.22 | 2.51 | 2.50 |
| Quick Ratio | 1.48 | 1.61 | 2.02 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €161.44 Million | €169.17 Million | €264.91 Million |
Boiron SA - Advanced Valuation Insights
This section examines the relationship between Boiron SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.22 |
| Latest Market Cap to Assets Ratio | 0.71 |
| Asset Growth Rate (YoY) | 4.6% |
| Total Assets | €602.81 Million |
| Market Capitalization | $428.29 Million USD |
Valuation Analysis
Below Book Valuation: The market values Boiron SA's assets below their book value (0.71x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Boiron SA's assets grew by 4.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Boiron SA (2001–2025)
The table below shows the annual total assets of Boiron SA from 2001 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €602.81 Million ≈ $704.75 Million |
+4.59% |
| 2024-12-31 | €576.33 Million ≈ $673.79 Million |
-2.35% |
| 2023-12-31 | €590.20 Million ≈ $690.01 Million |
-25.24% |
| 2022-12-31 | €789.49 Million ≈ $923.00 Million |
+2.44% |
| 2021-12-31 | €770.70 Million ≈ $901.03 Million |
-1.42% |
| 2020-12-31 | €781.82 Million ≈ $914.03 Million |
+2.29% |
| 2019-12-31 | €764.28 Million ≈ $893.53 Million |
-0.36% |
| 2018-12-31 | €767.08 Million ≈ $896.79 Million |
-4.16% |
| 2017-12-31 | €800.40 Million ≈ $935.76 Million |
+6.01% |
| 2016-12-31 | €755.03 Million ≈ $882.71 Million |
+8.57% |
| 2015-12-31 | €695.45 Million ≈ $813.05 Million |
+3.87% |
| 2014-12-31 | €669.55 Million ≈ $782.77 Million |
+0.29% |
| 2013-12-31 | €667.59 Million ≈ $780.48 Million |
+15.24% |
| 2012-12-31 | €579.28 Million ≈ $677.24 Million |
-1.42% |
| 2011-12-31 | €587.61 Million ≈ $686.97 Million |
+5.24% |
| 2010-12-31 | €558.34 Million ≈ $652.76 Million |
+6.98% |
| 2009-12-31 | €521.93 Million ≈ $610.20 Million |
+12.65% |
| 2008-12-31 | €463.34 Million ≈ $541.70 Million |
+8.16% |
| 2007-12-31 | €428.39 Million ≈ $500.83 Million |
+3.96% |
| 2006-12-31 | €412.06 Million ≈ $481.74 Million |
-3.56% |
| 2005-12-31 | €427.25 Million ≈ $499.50 Million |
+57.65% |
| 2004-12-31 | €271.02 Million ≈ $316.85 Million |
+9.29% |
| 2003-12-31 | €247.97 Million ≈ $289.91 Million |
+7.47% |
| 2002-12-31 | €230.73 Million ≈ $269.74 Million |
+12.08% |
| 2001-12-31 | €205.86 Million ≈ $240.67 Million |
-- |
About Boiron SA
Boiron SA manufactures and sells homeopathic medicines in France, rest of Europe, North America, and internationally. The company offers non-proprietary homeopathic medicines and homeopathic specialties; and other healthcare products, including medical devices, invitro diagnostics, herbal medicine, food supplements, cosmetics, and CBD-based products. It also provides homeopathic specialties compr… Read more